Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.

Al-Katib AM, Aboukameel A, Ebrahim A, Beck FW, Tekyi-Mensah SE, Raufi A, Ahmed Y, Mandziara M, Kafri Z.

Exp Hematol Oncol. 2014 Dec 19;3:31. doi: 10.1186/2162-3619-3-31. eCollection 2014.

2.

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM.

J Hematol Oncol. 2012 Sep 18;5:57. doi: 10.1186/1756-8722-5-57.

3.

Syncytial giant cell hepatitis associated with chronic lymphocytic leukemia: a case report.

Gupta E, Yacoub M, Higgins M, Al-Katib AM.

BMC Blood Disord. 2012 Jul 19;12:8. doi: 10.1186/1471-2326-12-8.

4.

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM.

Mol Cancer. 2009 Dec 3;8:115. doi: 10.1186/1476-4598-8-115.

5.

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.

Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.

Clin Cancer Res. 2009 Jun 15;15(12):4038-45. doi: 10.1158/1078-0432.CCR-08-2808. Epub 2009 Jun 9.

6.

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.

Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM.

J Hematol Oncol. 2009 Feb 16;2:8. doi: 10.1186/1756-8722-2-8.

7.

Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.

Beck FW, Eilender DS, Dandashi MH, Siddiq F, Snell DC, Godmere MA, Al-Katib AM, Mohammad RM.

Int J Mol Med. 2004 Jul;14(1):113-9.

PMID:
15202025
9.

The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R.

Semin Oncol. 2003 Apr;30(2):313-7.

PMID:
12720160
12.

Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM.

Clin Cancer Res. 2002 Aug;8(8):2735-41.

13.

Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.

Wall NR, Beck FW, Al-Katib AM, Mohammad RM.

J Drug Target. 2001;9(5):329-39.

PMID:
11770703
14.
15.

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.

Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM.

Invest New Drugs. 2001;19(3):245-7.

PMID:
11561682
16.

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.

Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM.

Anticancer Drugs. 2001 Jan;12(1):57-63.

PMID:
11272287
18.

Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.

Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM.

Anticancer Drugs. 2000 Jun;11(5):385-92.

PMID:
10912955
19.

Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.

Varterasian ML, Graff JJ, Severson RK, Weiss L, al-Katib AM, Kalemkerian GP.

Cancer Invest. 2000;18(4):303-8.

PMID:
10808365
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk